Role of linezolid in the treatment of complicated skin and soft tissue infections

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 357-366

  Peppard, William J ^a   Weigelt, John A ^b  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Antibiotic; Complicated skin and skin structure infections; cSSTI; Length of stay; Linezolid; MRSA; Oxazolidinone

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; ICLAPRIM; LINEZOLID; MINOCYCLINE; PENICILLIN G; RIFAMPICIN; SEROTONIN AGONIST; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BIOEQUIVALENCE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; COST BENEFIT ANALYSIS; DELIRIUM; DIABETIC FOOT; DIAPHORESIS; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; HYPERPYREXIA; HYPERREFLEXIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; PNEUMONIA; RESTLESSNESS; REVIEW; SEROTONIN SYNDROME; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREMOR; VOMITING;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; OXAZOLIDINONES; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS;

EID: 33745214003     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.357     Document Type: Review

References (93)

1. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41 (Suppl. 5), s341-s353 (2005).
2. Rennie RP, Jones RN, Mutnick AH, and the SENTRY program study group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY antimicrobial surveillance program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 45, 287-293 (2003).
3. Nichols RL. Optimal treatment of complicated skin and skin structure infection. J. Antimicrob. Chemother 44, 19-23 (1999).
4. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 22, 387-394 (1996).
5. Dupont H, Mentec H, Sollet JP, Bleichner J. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 27, 355-362 (2001).
6. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. Chest 115, 462-474 (1999).
7. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111, 676-685 (1997).
8. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156, 196-200 (1997).
9. Ruiz M, Torres A, Ewig S et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 162, 119-125 (2000).
10. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7, 178-182 (2001).
11. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infections. Clin. Infect. Dis. 36, 592-598 (2003).
12. Rubin RJ, Harrington CA, Poon A, Dietrick K, Greene JA, Moiduddin A. The economic impact of Staphyloccus aureus infection in New York City hospitals. Emerg. Infect. Dis. 5, 9-17 (1999).
13. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus. a review. Pharmacotherapy 25, 74-85 (2005).
14. CDC. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections - Los Angeles County, California, 2002-2003. MMWR Morb. Mortal. Wkly Rep. 52, 88 (2003).
15. CDC. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb. Mortal. Wkly Rep, 52, 793-795 (2003).
16. Kazakova SV, Hageman JC, Matava M et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 325, 468-475 (2005).
17. Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California, and Texas, 2001-2003. MMWR. Morb. Mortal. Wkly Rep. 52, 992-996 (2003).
18. CDC. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison - Mississippi, 2000. MMWR Morb. Mortal. Wkly Rep. 50, 919 (2001).
19. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin. Infect. Dis. 39, 971-979 (2004).
20. Nichols RL, Graham DR, Barriere SL et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicenter studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin. J. Antimicrob. Chemother. 44, 263-273 (1999).
21. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38, 1673-1681 (2004).
22. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother 55, 240-245 (2005).
23. Graham DR, Lucasti C, Malafaia O et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin. Infect. Dis. 34, 1460-1468 (2002).
24. Fabian TC, File TM, Embil JM et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg. Infect. 6, 269-282 (2005).
25. ® (linezolid) package insert. Pfizer, NY, USA (2005).
26. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138, 135-142 (2003).
27. Beringer P, Nguyen M, Hoem N et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob. Agents Chemother. 49, 3676-3681 (2005).
28. Wright DH, Pietz SL, Konstantinides FN, Rotschafer JC. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. J. Parenter. Enteral Nutr. 24, 42-48 (2000).
29. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45, 1843-1886 (2001).
30. Dehghanyar P, Burger C, Zeitlanger M et al. Penetration of linezolid into soft tissue of healthy volunteers after single and multiple doses. Antimicrob. Agents Chemother. 49, 2367-2371 (2005).
31. Boselli E, Breilh D, Rimmele T et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med. 33, 1529-1533 (2005).
32. Stein GE, Schooley SL, Peloquin CA et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulites. Ann. Pharmacother. 39, 427-432 (2005).
33. Brier ME, Stalker DJ, Aronoff GR et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob. Agents Chemother. 47, 2775-2780 (2003).
34. Fiaccadori E, Maggiore U, Rotelli C et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit. Care Med 32, 2437-2442 (2004).
35. Pea F, Viale P, Lugno M et al. Linezolid disposition after standard dosage in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am. J. Kidney Dis. 44, 1071-1075 (2004).
36. Kraft MD, Pasko DA, Depestel DD et al. Linezolid clearance during continuous venovenous hemodiafiltration: a case report. Pharmacotherapy 23, 1071-1075 (2003).
37. Trotman RL, Williamson JC, Shoemaker M et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41, 1159-1166 (2005).
38. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44, 3408-3413 (2000).
39. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49, 2260-2266 (2005).
40. Weigelt J, Kaafarani H, Itani K, Swanson R. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188, 760-766 (2004).
41. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven grampositive infections. J. Antimicrob. Chemother. 53, 335-344 (2004).
42. Malone DC. The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J. Manag. Care Pharm. 11, S7-S10 (2005).
43. Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmacoeconomics - an aid to better decision making. J. Eur. Acad. Dermatol. Venereol. 19, 34-39 (2005).
44. Paladino JA. Economics of antibiotic use policies. Pharmacotheraphy 24, 232S-238S (2004).
45. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylcoccus aureus infections. Clin. Infect. Dis, 34, 1481-1490 (2002).
46. Tice AD, Hoaglund PA, Nolet B, McKinnon PS, Mozaffari E. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 22, 63S-70S (2002).
47. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 189, 425-428 (2005).
48. Li Z, Wilike RJ, Pinto LA et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized multicenter trial. Pharmacotherapy 21, 263-274 (2001).
49. Cosgrove SE, Qi Y, Kaye KS, Harbath S, Karchmer AW. Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control. Hosp. Epidemiol. 26, 166-174 (2005).
50. Shorr AF, Susla GM, Kolleff MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit. Care Med. 32, 137-143 (2004).
51. Herrerp IA, Issa NC, Patel R. Nosocomial spread of linezolid resistant vancomycin resistant Enterococcus faecium. N. Engl. J. Med. 346, 3408-3413 (2002).
52. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann. Pharmacother. 37, 769-774 (2003).
53. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance is a clinical isolate of Staphylococcus aureus. [Letter]. Lancet 358, 207-208 (2001).
54. Xiong L, Kloss P, Douthwaite S et al. Ozazolidinone resistance mutations in 23s rRNA of Escherichia coli reveal central region of domain V as the primary site of drug action. J. Bacteriol. 182, 5325-5331 (2000).
55. Wilson P, Andrews JA, Charlesworth R et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. [Letter]. J. Antimicrob. Chemother. 51, 186-188 (2003).
56. Peterson DL, Pasculle AW, McCurry K. Linezolid: the first oxazolidinone antimicrobial. [Letter]. Ann. Intern. Med. 139, 863-864 (2003).
57. Machado ARL, Andrade SS, Barth AL et al. The emergence of linezolid-resistance among Staphylococcus aureus from cystic fibrosis patients. Program and abstracts in the 43rd International Conference on Antimicrobial Agents and Chemotherapy. IL, USA, C2-1825 (2003).
58. Meka VG, Pillai SK, Sakoulas G et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190, 311-317 (2004).
59. Meka VG, Gold HS, Cooke A et al. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J. Antimicrob. Chemother 54, 818-820 (2004).
60. Peters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am. J. Med. Sci. 330, 102-105 (2005).
61. ® Annual Appraisal of Potency and Spectrum (ZAAPS) program assessing isolated from 16 countries. J. Antimicrob. Chemother. 57, 279-287 (2006).
62. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized double blind multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 32, 402-412 (2003).
63. Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin. Infect. Dis. 37, 1609-1616 (2003).
64. Attassi K, Hershberger E, Alam R et al. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34, 695-698 (2002).
65. Orrick JJ, Johns T, Janelle J et al. Thrombocytopenia secondary to linezolid administration: what is the risk. Clin. Infect. Dis. 35, 348-349 (2002).
66. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob, Agents Chemother. 46, 2723-2726 (2002).
67. Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J. Antimicrob. Chemother. 54, 832-835 (2004).
68. Lavery S, Ravi H, McDaniel WW et al. Linezolid and serotonin syndrome. Psychosomatics 42, 432-434 (2001).
69. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin. Infect. Dis. 34, 1651-1652 (2002).
70. Hachem RY, Hicks K, Huen A et al. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin. Infect. Dis. 37, e8-e11 (2003).
71. Bernard L, Stern R, Lew D et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin. Infect. Dis. 36, 1197 (2003).
72. Morales-Molina JA, Mateu-de Antonio J, Grau Cerrato S et al. Probable serotonin syndrome by interaction of amitriptyline, paroxetine and linezolid. Farm. Hosp. 29, 292-293 (2005).
73. Jones SL, Athan E, O'Brien D. Serotonin syndrome due to co-administration of linezolid and venlafaxine. J. Antimicrob. Chemother. 54, 289-290 (2004).
74. Thomas CR, Rosenberg M, Blythe V et al. Serotonin syndrome and linezolid. J. Am. Acad. Child Adolesc. Psychiatry 43, 790 (2004).
75. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram. J. Am. Med. Dir. Assoc. 5, 111-113 (2004).
76. Bergeron L, Boule M, Perrault S. Serotonin toxicity associated with concomitant use of linezolid. Ann. Pharmacother. 39, 956-961 (2005).
77. Morales N, Vermette H. Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine. Psychosomatics 46, 274-275 (2005).
78. Morales-Molina J, Mateu-de Antonia J, Marin-Casino M, Grau S. Linezolid-associated serotonin syndrome: what we can learn from cases reported so far. J. Antimicrob. Chemother. 56, 1176-1178 (2005).
79. Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy. Am. J. Ophthalmol. 139, 1114-1116 (2005).
80. Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT. Linezolid-associated peripheral neuropathy. Mayo Clin. Proc. 79, 927-930 (2004).
81. Baddour LM, Wilson WR, Bayer AS et al. AHA scientific statement on infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 111, 3167-3184 (2005).
82. American Thoracic Society and Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416 (2005).
83. Allan R, Tunkel AR, Barry J et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39, 1267-1284 (2004).
84. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis, 41, 1373-1406 (2005).
85. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38, 1279-1286 (2004).
86. Pace JL, Krause K, Johnston D et al. In vitro activity of telavancin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 302-304 (2004).
87. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly, bactericidal, concentration-dependant anti-infective with multiple mechanisms of action against gram-positive bacteria. J. Antimicrob. Chemother. 53, 797-803 (2004).
88. Tenover FC, Weigel LM, Appelbaum PC et al. Vancomycin-resistant Staphylcoccus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48, 275-280 (2005).
89. Hegde S, Reyes N, Wiens T et al. Pharmacodynamics of telavancin, a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 38, 3043-3050 (2004).
90. Stryjewski ME, O'Riorden WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect Dis. 40, 1601-1607 (2005).
91. Lin G, Credito, K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dabavancin, an experimental glycopeptide. Antimicrob. Agents Chemother, 49, 770-772 (2005).
92. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48, 137-143 (2004).
93. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41, 1407-1415 (2005).